NCT05129423View on ClinicalTrials.gov

A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

August 31, 2024

Conditions
Chronic Spontaneous Urticaria
Interventions
DRUG

MTPS9579A

MTPS9579A will be administered.

DRUG

Placebo

Placebo matched with MTPS9579A will be administered.

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY